AbbVie Inc.ABBVNYSE

Overview Intelligence Charts News Fundamentals

Analyst Sentiment

Analysts lean bullish — 72% recommend buying.

Consensus Rating

Buy

25 analysts·High coverage

72%

Rating Distribution

Strong Buy

00%

Buy

1872%

Hold

728%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 10% higher.

Bear Case

$223.00

-5%

Consensus

$256.15

+10%

Bull Case

$299.00

+28%

Price Range25 analysts

Low

Consensus

High

$223.00

$299.00

Current Target

Current Price

$233.86

Upside to Target

$22.29

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$14.56(18 analysts)

P/E99x

Current: 98.5x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+8.11%

EPS+11.16%

FY2028

Rev+7.33%

EPS+10.28%

FY2029

Rev+5.52%

EPS+9.43%

Earnings Surprises

Beat rate:92%(11/12 quarters)

Avg surprise:+0.3%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 24, 2026RBC Capital

RBC Capital Starts Abbvie (ABBV) at Outperform

Target:$260.00

+13.8%from $228.44

Feb 19, 2026Barclays

AbbVie initiated with an Overweight at Barclays

Target:$275.00

+22.6%from $224.35

Feb 18, 2026Piper Sandler

AbbVie price target raised to $299 from $289 at Piper Sandler

Target:$299.00

+28.4%from $232.86

Feb 5, 2026UBS

AbbVie price target lowered to $230 from $240 at UBS

Target:$230.00

+5.8%from $217.41

Feb 4, 2026Evercore ISI

AbbVie price target lowered to $228 from $232 at Evercore ISI

Target:$228.00

+5.1%from $217.02

Jan 28, 2026Goldman Sachs

Goldman Sachs Reiterates Neutral Rating on Abbvie (ABBV) Ahead of Earnings

Target:$223.00

+1.5%from $219.77

Jan 20, 2026Berenberg Bank

AbbVie price target raised to $275 from $270 at Berenberg

Target:$275.00

+28.3%from $214.35

Jan 15, 2026BMO Capital

BMO Capital Reiterates Outperform Rating on Abbvie (ABBV)

Target:$258.00

+18.5%from $217.74

Jan 7, 2026UBS

AbbVie assumed with a Neutral at UBS

Target:$240.00

+7.2%from $223.93

Dec 12, 2025Morgan Stanley

AbbVie price target raised to $269 from $261 at Morgan Stanley

Target:$269.00

+20.9%from $222.48

Dec 10, 2025HSBC

AbbVie upgraded to Buy from Hold at HSBC

Target:$265.00

+18.8%from $222.99

Nov 5, 2025Piper Sandler

AbbVie price target raised to $289 from $284 at Piper Sandler

Target:$289.00

+35.3%from $213.57

Nov 3, 2025Raymond James

Abbvie (ABBV) PT Raised to $256 at Raymond James

Target:$256.00

+17.4%from $218.04

Oct 20, 2025Guggenheim

AbbVie price target raised to $242 from $227 at Guggenheim

Target:$242.00

+5.4%from $229.57

Oct 17, 2025Raymond James

AbbVie price target raised to $250 from $236 at Raymond James

Target:$250.00

+10.2%from $226.87

Oct 10, 2025Piper Sandler

AbbVie price target raised to $284 from $231 at Piper Sandler

Target:$284.00

+23.1%from $230.69

Oct 9, 2025Cantor Fitzgerald

AbbVie price target raised to $250 from $245 at Cantor Fitzgerald

Target:$250.00

+8.1%from $231.24

Oct 3, 2025UBS

AbbVie price target raised to $251 from $220 at BofA

Target:$251.00

+6.1%from $236.56

Oct 2, 2025HSBC

AbbVie downgraded to Hold from Buy at HSBC (yesterday)

Target:$225.00

-7.9%from $244.38

Sep 15, 2025Cantor Fitzgerald

AbbVie price target raised to $245 from $215 at Cantor Fitzgerald

Target:$245.00

+12.2%from $218.34

Feb 3, 2025Raymond James

AbbVie price target raised to $220 from $218 at Raymond James

Target:$220.00

+15.7%from $190.14

Feb 3, 2025BMO Capital

AbbVie price target raised to $215 from $208 at BMO Capital

Target:$215.00

+13.1%from $190.14

Nov 12, 2024BMO Capital

Abbvie (ABBV) PT Lowered to $208 at BMO Capital

Target:$208.00

+3.2%from $201.61

Oct 31, 2024BMO Capital

Abbvie (ABBV) PT Raised to $228 at BMO Capital

Target:$228.00

+13.2%from $201.50

Oct 31, 2024Bank of America Securities

AbbVie price target raised to $210 from $195 at BofA

Target:$210.00

+4.2%from $201.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance